347 related articles for article (PubMed ID: 28202824)
1. [Disease-Modifying Therapy for Parkinson's Disease].
Shimura H; Hattori N
Brain Nerve; 2017 Feb; 69(2):159-165. PubMed ID: 28202824
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic approaches to target alpha-synuclein pathology.
Brundin P; Dave KD; Kordower JH
Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
5. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
6. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
7. Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
[TBL] [Abstract][Full Text] [Related]
8. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
9. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Török N; Majláth Z; Szalárdy L; Vécsei L
Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
[TBL] [Abstract][Full Text] [Related]
10. The pathogenesis of Parkinson's disease.
Morris HR; Spillantini MG; Sue CM; Williams-Gray CH
Lancet; 2024 Jan; 403(10423):293-304. PubMed ID: 38245249
[TBL] [Abstract][Full Text] [Related]
11. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.
Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
13. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases.
Shannon KM; Keshavarzian A; Dodiya HB; Jakate S; Kordower JH
Mov Disord; 2012 May; 27(6):716-9. PubMed ID: 22550057
[TBL] [Abstract][Full Text] [Related]
14. Viral vectors as a tool to model and treat Parkinson's disease.
Bensadoun JC; Aebischer P
Wien Klin Wochenschr; 2006 Oct; 118(19-20):568-70. PubMed ID: 17136329
[No Abstract] [Full Text] [Related]
15. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
[TBL] [Abstract][Full Text] [Related]
16. Retinal α-synuclein deposits in Parkinson's disease patients and animal models.
Veys L; Vandenabeele M; Ortuño-Lizarán I; Baekelandt V; Cuenca N; Moons L; De Groef L
Acta Neuropathol; 2019 Mar; 137(3):379-395. PubMed ID: 30721408
[TBL] [Abstract][Full Text] [Related]
17. Research in motion: the enigma of Parkinson's disease pathology spread.
Brundin P; Li JY; Holton JL; Lindvall O; Revesz T
Nat Rev Neurosci; 2008 Oct; 9(10):741-5. PubMed ID: 18769444
[TBL] [Abstract][Full Text] [Related]
18. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
19. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
Bobela W; Aebischer P; Schneider BL
Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
